Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi PharmaTech to List Shares in CMO Subsidiary on China's Third Board

publication date: Apr 2, 2015
WuXi PharmaTech sold a 5.55% stake in SynTheAll Pharma, its chemical drug contract manufacturing subsidiary, to management of STA and WuXi for $28 million. The company also received permission to list STA shares on the New Third Board OTC exchange starting April 3. The owners of the STA shares may sell one-third of their shares on the exchange over the next year, establishing a price for STA. WuXi will not list additional shares at this time, but it has the flexibility to do so later, probably after STA migrates to Shenzhen's GEM exchange. More details....

Stock Symbol: (NYSE: WX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital